226 related articles for article (PubMed ID: 19351960)
1. Ectopic expression of B-lymphoid kinase in cutaneous T-cell lymphoma.
Krejsgaard T; Vetter-Kauczok CS; Woetmann A; Kneitz H; Eriksen KW; Lovato P; Zhang Q; Wasik MA; Geisler C; Ralfkiaer E; Becker JC; Ødum N
Blood; 2009 Jun; 113(23):5896-904. PubMed ID: 19351960
[TBL] [Abstract][Full Text] [Related]
2. B-lymphoid tyrosine kinase (Blk) is an oncogene and a potential target for therapy with dasatinib in cutaneous T-cell lymphoma (CTCL).
Petersen DL; Krejsgaard T; Berthelsen J; Fredholm S; Willerslev-Olsen A; Sibbesen NA; Bonefeld CM; Andersen MH; Francavilla C; Olsen JV; Hu T; Zhang M; Wasik MA; Geisler C; Woetmann A; Odum N
Leukemia; 2014 Oct; 28(10):2109-12. PubMed ID: 24919804
[No Abstract] [Full Text] [Related]
3. A novel BLK-induced tumor model.
Petersen DL; Berthelsen J; Willerslev-Olsen A; Fredholm S; Dabelsteen S; Bonefeld CM; Geisler C; Woetmann A
Tumour Biol; 2017 Jul; 39(7):1010428317714196. PubMed ID: 28670978
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of IkappaB kinase subunit 2 in cutaneous T-cell lymphoma down-regulates nuclear factor-kappaB constitutive activation, induces cell death, and potentiates the apoptotic response to antineoplastic chemotherapeutic agents.
Sors A; Jean-Louis F; Bégué E; Parmentier L; Dubertret L; Dreano M; Courtois G; Bachelez H; Michel L
Clin Cancer Res; 2008 Feb; 14(3):901-11. PubMed ID: 18245554
[TBL] [Abstract][Full Text] [Related]
5. Malignant transformation of early lymphoid progenitors in mice expressing an activated Blk tyrosine kinase.
Malek SN; Dordai DI; Reim J; Dintzis H; Desiderio S
Proc Natl Acad Sci U S A; 1998 Jun; 95(13):7351-6. PubMed ID: 9636152
[TBL] [Abstract][Full Text] [Related]
6. PAK1 overexpression promotes cell proliferation in cutaneous T cell lymphoma via suppression of PUMA and p21.
Wang Y; Gu X; Li W; Zhang Q; Zhang C
J Dermatol Sci; 2018 Apr; 90(1):60-67. PubMed ID: 29307600
[TBL] [Abstract][Full Text] [Related]
7. Telomerase functions beyond telomere maintenance in primary cutaneous T-cell lymphoma.
Chevret E; Andrique L; Prochazkova-Carlotti M; Ferrer J; Cappellen D; Laharanne E; Idrissi Y; Boettiger A; Sahraoui W; Ruiz F; Pham-Ledard A; Vergier B; Belloc F; Dubus P; Beylot-Barry M; Merlio JP
Blood; 2014 Mar; 123(12):1850-9. PubMed ID: 24470590
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic Silencing of Tumor Suppressor miR-124 Directly Supports STAT3 Activation in Cutaneous T-Cell Lymphoma.
García-Colmenero L; González J; Sandoval J; Guillén Y; Diaz-Lagares A; Andrades E; Iglesias A; Nonell L; Pujol RM; Bigas A; Espinosa L; Gallardo F
Cells; 2020 Dec; 9(12):. PubMed ID: 33333886
[TBL] [Abstract][Full Text] [Related]
9. miR-337 suppresses cutaneous T-cell lymphoma via the STAT3 pathway.
Xia L; Wu L; Xia H; Bao J; Li Q; Chen X; Xia R
Cell Cycle; 2019 Jul; 18(14):1635-1645. PubMed ID: 31213131
[TBL] [Abstract][Full Text] [Related]
10. Down-regulating constitutive activation of the NF-kappaB canonical pathway overcomes the resistance of cutaneous T-cell lymphoma to apoptosis.
Sors A; Jean-Louis F; Pellet C; Laroche L; Dubertret L; Courtois G; Bachelez H; Michel L
Blood; 2006 Mar; 107(6):2354-63. PubMed ID: 16219794
[TBL] [Abstract][Full Text] [Related]
11. High expression of Dicer reveals a negative prognostic influence in certain subtypes of primary cutaneous T cell lymphomas.
Valencak J; Schmid K; Trautinger F; Wallnöfer W; Muellauer L; Soleiman A; Knobler R; Haitel A; Pehamberger H; Raderer M
J Dermatol Sci; 2011 Dec; 64(3):185-90. PubMed ID: 21937200
[TBL] [Abstract][Full Text] [Related]
12. Telomerase activity and telomere length in lymphocytes from patients with cutaneous T-cell lymphoma.
Wu K; Lund M; Bang K; Thestrup-Pedersen K
Cancer; 1999 Sep; 86(6):1056-63. PubMed ID: 10491534
[TBL] [Abstract][Full Text] [Related]
13. Disruption of CCL20-CCR6 interaction inhibits metastasis of advanced cutaneous T-cell lymphoma.
Ikeda S; Kitadate A; Ito M; Abe F; Nara M; Watanabe A; Takahashi N; Miyagaki T; Sugaya M; Tagawa H
Oncotarget; 2016 Mar; 7(12):13563-74. PubMed ID: 26789110
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of c-myb in leukaemic and non-leukaemic variants of cutaneous T-cell lymphoma.
Poenitz N; Simon-Ackermann J; Gratchev A; Qadoumi M; Klemke CD; Stadler R; Kremer A; Radenhausen M; Henke U; Assaf C; Utikal J; Goerdt S; Dippel E
Dermatology; 2005; 211(2):84-92. PubMed ID: 16088151
[TBL] [Abstract][Full Text] [Related]
15. Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-Cell lymphoma.
Sibbesen NA; Kopp KL; Litvinov IV; Jønson L; Willerslev-Olsen A; Fredholm S; Petersen DL; Nastasi C; Krejsgaard T; Lindahl LM; Gniadecki R; Mongan NP; Sasseville D; Wasik MA; Iversen L; Bonefeld CM; Geisler C; Woetmann A; Odum N
Oncotarget; 2015 Aug; 6(24):20555-69. PubMed ID: 26244872
[TBL] [Abstract][Full Text] [Related]
16. Differential effects of interleukin-2 and interleukin-15 versus interleukin-21 on CD4+ cutaneous T-cell lymphoma cells.
Marzec M; Halasa K; Kasprzycka M; Wysocka M; Liu X; Tobias JW; Baldwin D; Zhang Q; Odum N; Rook AH; Wasik MA
Cancer Res; 2008 Feb; 68(4):1083-91. PubMed ID: 18281483
[TBL] [Abstract][Full Text] [Related]
17. Increased CCL18 expression in patients with cutaneous T-cell lymphoma: association with disease severity and prognosis.
Miyagaki T; Sugaya M; Suga H; Ohmatsu H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
J Eur Acad Dermatol Venereol; 2013 Jan; 27(1):e60-7. PubMed ID: 22404649
[TBL] [Abstract][Full Text] [Related]
18. Aberrant CD137 ligand expression induced by GATA6 overexpression promotes tumor progression in cutaneous T-cell lymphoma.
Kamijo H; Miyagaki T; Shishido-Takahashi N; Nakajima R; Oka T; Suga H; Sugaya M; Sato S
Blood; 2018 Nov; 132(18):1922-1935. PubMed ID: 30194255
[TBL] [Abstract][Full Text] [Related]
19. IL-22, but not IL-17, dominant environment in cutaneous T-cell lymphoma.
Miyagaki T; Sugaya M; Suga H; Kamata M; Ohmatsu H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
Clin Cancer Res; 2011 Dec; 17(24):7529-38. PubMed ID: 22048239
[TBL] [Abstract][Full Text] [Related]
20. ALK-positive primary cutaneous T-cell-lymphoma (CTCL) with unusual clinical presentation and aggressive course.
Wehkamp U; Oschlies I; Nagel I; Brasch J; Kneba M; Günther A; Klapper W; Weichenthal M
J Cutan Pathol; 2015 Nov; 42(11):870-7. PubMed ID: 26053561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
